L'identification du virus de l'influenza à l'aide de l'immunoperoxydase

1973 ◽  
Vol 19 (1) ◽  
pp. 147-149 ◽  
Author(s):  
R. Dobardzic ◽  
A. Boudreault ◽  
V. Pavilanis

The specific antibodies anti-influenza virus A2/Aichi/68 were combined immunologically with the virus purified by zonal centrifugation, then dissociated by lowering the pH and conjugated with horseradish peroxidase using glutaraldehyde as the coupling agent. With so labeled antibodies it was possible to detect the viral antigen in infected chick embryo kidney cells with the light microscope. This work suggests that the immunoperoxidase technique could be useful for early rhinocytologic diagnosis of influenza virus infections.

1961 ◽  
Vol 7 (3) ◽  
pp. 347-353 ◽  
Author(s):  
A. Boudreault ◽  
V. Pavilanis

Quantitative relations between hemadsorption, hemagglutination, and cytopathogenicity of influenza virus strains have been studied. The influenza virus has been cultivated on monkey kidney, chick kidney, and chick embryo cells.It was shown that hemadsorption can also be used for titration of influenza virus adapted on tissue culture.This technic is a reliable and sensitive one. It was also found that the growth of influenza virus is better in a medium of neutral pH and that chicks' age is not an important factor in the multiplication of the virus on chick kidney cells.


2019 ◽  
Author(s):  
Magen E. Francis ◽  
Mara McNeil ◽  
Morgan L. King ◽  
Ted M. Ross ◽  
Alyson A. Kelvin

ABSTRACTInfluenza virus infections are a recurrent public health problem causing millions of hospitalizations each year despite vaccination efforts. The well-known yearly cycling of influenza viruses is the result of the reciprocal and coevolutionary relationship between the host and virus. Together, from the frequent infections and yearly vaccinations humans build a complex immune history over their lifetimes. Despite the prominence of immune history, vaccines are rarely evaluated in the imprinted (preimmune) host. We developed a ferret model for this purpose where ferrets were imprinted with a sublethal dose of the historical seasonal H1N1 strain A/USSR/90/1977 (USSR/77). A +60 day recovery period was given to build immune memory prior to vaccination with a split virion QIV vaccine. To evaluate protection, the ferrets were challenged with a 2009 H1N1 pandemic virus matching the vaccine antigens. The preimmune-vaccinated ferrets did not experience significant disease during challenge while the naïve-vaccinated group were the most severe. Hemagglutination inhibition (HAI) assays showed that preimmune ferrets had a faster and longer antibody response post vaccination for all vaccine antigens compared to minimal HAI responses in the naïve-vaccinated group. To investigate the immune mechanisms leading to disease protection in the preimmune ferrets, we performed microneutralization and isotype ELISA assays. Microneutralization suggested preimmune ferrets developed antibodies that were more functional for virus neutralization. Antibody isotype profiling indicated that virus specific antibodies in the preimmune-vaccinated ferrets was dominated by the IgG isotype suggesting B cell maturity and possible plasticity in a pre-existing B cell. Surprisingly, the naïve-vaccinated ferrets developed a more severe disease with less virus neutralization suggesting improper immunological processing of vaccine antigens. Together, these results showed the preimmune host had greater responses to vaccination, and the predominant IgG virus specific antibodies suggested a flexible long-lived B cell response. These results are important and should be considered for vaccine design.AUTHOR SUMMARYThe influenza virus is a significant threat to human health and the economy despite large-scale vaccination efforts. The low effectiveness of the seasonal influenza vaccine is attributed to the frequently mutating virus enabling people to have several influenza virus infections throughout their lifetimes. As people are susceptible to multiple infections, they build a complex immune history. Despite this, vaccines are often not evaluated in animals with an immune history. Here we developed a ferret model that had previously been infected with a historical influenza virus to evaluate vaccine responses to current vaccines. Ferrets were infected with a sublethal does of a historical virus, A/USSR/90/1977, to develop a preimmune background. Preimmune ferrets were vaccinated with the Sanofi quadrivalent influenza vaccine and the antibody responses were investigated after vaccination. Our results showed that preimmune ferrets had a stronger antibody response following vaccination and the antibodies developed were older and better at neutralizing influenza virus at a virus challenge. Clinically, preimmune-vaccinated ferrets developed a milder disease during challenge compared to naïve-vaccinated ferrets. This work indicates that the host responses to vaccination are dependent on the host background and that influenza vaccine development and evaluation should take host influenza background into account.


Author(s):  
D. R. Abrahamson ◽  
P. L. St.John ◽  
E. W. Perry

Antibodies coupled to tracers for electron microscopy have been instrumental in the ultrastructural localization of antigens within cells and tissues. Among the most popular tracers are horseradish peroxidase (HRP), an enzyme that yields an osmiophilic reaction product, and colloidal gold, an electron dense suspension of particles. Some advantages of IgG-HRP conjugates are that they are readily synthesized, relatively small, and the immunolabeling obtained in a given experiment can be evaluated in the light microscope. In contrast, colloidal gold conjugates are available in different size ranges and multiple labeling as well as quantitative studies can therefore be undertaken through particle counting. On the other hand, gold conjugates are generally larger than those of HRP but usually can not be visualized with light microscopy. Concern has been raised, however, that HRP reaction product, which is exquisitely sensitive when generated properly, may in some cases distribute to sites distant from the original binding of the conjugate and therefore result in spurious antigen localization.


2019 ◽  
Vol 20 (13) ◽  
pp. 1108-1121 ◽  
Author(s):  
Miriam Dibo ◽  
Eduardo C. Battocchio ◽  
Lucas M. dos Santos Souza ◽  
Matheus D. Veloso da Silva ◽  
Bruna K. Banin-Hirata ◽  
...  

The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases.


Sign in / Sign up

Export Citation Format

Share Document